Q4 2026 Alkem Laboratories Ltd Earnings Call Transcript
Key Points
- Alkem Laboratories Ltd (BOM:539523) achieved a record profitability with EBITDA surpassing INR3,000 crores, reflecting strong business growth and operational excellence.
- The company reported a 14.6% year-over-year growth in total revenue for Q4 FY26, driven by strong performance in both domestic and international markets.
- Successful launch of semaglutide in March 2026, capturing an 11% market share according to the latest IQVIA report, indicating strong traction in the chronic segment.
- International sales grew by 25.4% year-over-year, supported by new launches and market expansion, showcasing robust international business growth.
- The company maintained a disciplined approach to cost management, resulting in a meaningful margin expansion with an EBITDA margin of 20.4% for FY26.
- The geopolitical environment and evolving global supply chain dynamics have led to increased logistics costs and pressure on APIs and packaging materials, posing near-term headwinds.
- Trade generic business growth was limited to 4.3% due to restructuring challenges, impacting overall domestic sales growth.
- The company faces regulatory pricing pressures and global competition, which could affect future profitability and market positioning.
- R&D expenses increased to 6.4% of total revenue in Q4 FY26, which may impact short-term profitability despite being aligned with annual guidance.
- The US biologic plant is not yet EBITDA positive, and it will take time to achieve breakeven, affecting overall financial performance in the near term.
Ladies and gentlemen, good day, and welcome to the Alkem Laboratories Limited Q4 FY26 earnings conference call hosted by Motilal Oswal Financial Services Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Tushar Manudhane from Motilal Oswal Financial Services. Thank you, and over to you, sir.
Thanks, Davin. Good evening, and a warm welcome for fourth-quarter FY26 earnings call of Alkem Laboratories. From the management side, we have Mr. Sandeep Singh, Managing Director; Dr. Vikas Gupta, CEO; Mr. Nitin Agarwal, CFO; and Ms. Purvi Shah, Head of Investor Relations.
Over to you, Purvi.
Thank you, Tushar. Good evening, everyone. On behalf of Alkem Laboratories, I welcome you all to our Q4 and FY26 earnings conference call. We are happy to have our Managing Director, Mr. Sandeep Singh, on the call today to engage directly with all
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
